394 results on '"Mammary analogue secretory carcinoma"'
Search Results
52. Secretory Carcinoma of the Salivary Gland – Systematic Review of the Literature and Report of 2 Cases
- Author
-
Scott M. Peters, Stewart K. Lazow, Eric Silver, Steve Yusupov, and Marshall P. Solomon
- Subjects
medicine.medical_specialty ,Breast Neoplasms ,Salivary Glands ,Metastasis ,Nodal status ,medicine ,Humans ,Salivary gland ,business.industry ,Mammary analogue secretory carcinoma ,Mortality rate ,Carcinoma ,Middle Aged ,Salivary Gland Neoplasms ,medicine.disease ,Dermatology ,Middle age ,Secretory Carcinoma ,medicine.anatomical_structure ,Otorhinolaryngology ,Localized disease ,Female ,Surgery ,Mammary Analogue Secretory Carcinoma ,Oral Surgery ,business - Abstract
Purpose Secretory carcinoma (SC) of the salivary gland, formerly known as mammary analogue secretory carcinoma, is an uncommon and fairly newly described, low grade malignant neoplasm of the salivary gland. Given the small number of cases reported in the literature to date, treatment guidelines are scarce. This study aimed to describe the clinical characteristics of SC, discuss prior management strategies, and provide recommendations for future treatment. Methods We performed a systematic review of all the cases of SC reported in the literature since it was first recognized in 2010. Using Pubmed, Crossref, and Google Scholar, we identified all articles reporting cases of SC. Results We identified 657 cases of SC in 109 articles. In addition, we provided 2 new cases, for a total of 659 cases in 110 articles. To our knowledge, this is the largest review of cases of SC in the literature to date. We summarized the clinical characteristics of SC, as well as the nodal status, clinical management, recurrence rate, and death rate. Conclusions SC occurs on average in middle age (with a large age range), presents most often initially as localized disease without metastasis, and has a low but not insignificant recurrence rate. Deaths have been reported. The generalized recommendations for treatment of SC are in line with those of other low-grade salivary gland malignancies.
- Published
- 2022
53. Mammary analogue secretory carcinoma: A rare salivary gland tumour
- Author
-
B S Jackson, T L Pratt, and A van Rooyen
- Subjects
Mammary analogue secretory carcinoma ,Salivary gland ,Parotid ,Tumour ,Medicine ,Medicine (General) ,R5-920 - Abstract
Mammary analogue secretory carcinoma (MASC) is a rare and recently described tumour of the salivary glands. MASC has similar histomorphological and immunohistochemical features of secretory carcinoma of the breast. MASC can be mistaken for other salivary gland tumours, especially acinic cell carcinoma. A 28-year-old man was diagnosed with a rare salivary gland tumour in Pretoria, South Africa (SA). To our knowledge, a report of MASC in SA has not previously been published. The surgeons dealing with salivary gland tumours should be aware of the clinical presentation. Current treatment is similar to that of other salivary gland malignancies.
- Published
- 2017
- Full Text
- View/download PDF
54. ETV6–NTRK3-positive parotid mammary analogue secretory carcinoma: a case report
- Author
-
María Soledad Rodríguez Duque, Juan Rodríguez Cobo, Eduardo Ibaseta Fidalgo, Carmen Vallejo Secadas, Julia Medina Del Valle, Javier Gómez Román, Javier Freire Salinas, Marta María Mayorga Fernández, Servando Lazuén Fernández, and Javier Álvarez Gama
- Subjects
Male ,Embryology ,medicine.medical_specialty ,Oncogene Proteins, Fusion ,medicine.medical_treatment ,Case Report ,Malignancy ,Translocation, Genetic ,Pathology and Forensic Medicine ,head and neck ,Biomarkers, Tumor ,medicine ,Humans ,salivary ,cancer ,Aged ,Salivary gland ,business.industry ,Cancer ,Neck dissection ,Cell Biology ,General Medicine ,Parotidectomy ,Salivary Gland Neoplasms ,medicine.disease ,ETV6 ,medicine.anatomical_structure ,Superficial Parotidectomy ,parotid ,Mammary Analogue Secretory Carcinoma ,Radiology ,Differential diagnosis ,business ,Developmental Biology - Abstract
Introduction Mammary analogue secretory carcinoma (MASC) is a recent discovered entity of salivary glands tumors, reported for first time in 2010. The presence of a translocation encodes the ETS variant transcription factor 6-neurotrophic tyrosine receptor kinase (ETV6-NTRK3) gene fusion differences MASC from other tumors. Case presentation A 68-year-old male showed a non-painful right parotid enlargement, came from dermatology service, and followed by some facial squamous cell carcinomas. A computed tomography (CT) scan showed a 1.7×1.6 cm right parotid enlargement in superficial lobe. The patient underwent a right superficial parotidectomy. The final pathology confirmed the presence of ETV6-NTRK3-positive MASC. Complete right deep parotidectomy and functional cervical emptying were performed. Discussions and conclusions It is necessary to establish an appropriated differential diagnosis between salivary gland tumors. MASC is a low-grade malignancy cancer that sometimes can evolve to a high-grade tumor that might produce local and distance dissemination. Most times, these tumors are only treated by surgical resection and evaluating by a multidisciplinary team the need of more treatments. In our case, the patient showed a primary parotid tumor, removed surgically with free edges, and being identified as MASC. We decided to underwent neck dissection and discovered a second MASC focus on cervical salivary gland; however, there was no nodal dissemination. The patient remains disease-free after 14 months from last surgery. It is important to keep studying genetic therapy targets to ETV6-NTRK3 to obtain a new therapy line to treat those cases that require.
- Published
- 2021
55. Radiological features of head and neck mammary analogue secretory carcinoma: 11 new cases with a systematic review of 29 cases reported in 28 publications
- Author
-
Yoshiaki Ota, Mariko Kurokawa, Akira Baba, Ryo Kurokawa, Ashok Srinivasan, and Toshio Moritani
- Subjects
Male ,medicine.medical_specialty ,Metastasis ,Biomarkers, Tumor ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Retrospective Studies ,Neuroradiology ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,Retrospective cohort study ,Salivary Gland Neoplasms ,medicine.disease ,Parotid gland ,Radiography ,Exact test ,medicine.anatomical_structure ,Radiological weapon ,Mammary Analogue Secretory Carcinoma ,Neurology (clinical) ,Neurosurgery ,Radiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
This retrospective study aimed to investigate the radiological features of head and neck mammary analogue secretory carcinoma (MASC) and systematically review previous publications and 11 new cases. We included patients with pathologically proven MASCs with preoperative CT or MRI images, including 11 patients from our hospital and 29 patients from 28 publications extracted after screening 645 abstracts. Two board-certified radiologists reviewed and evaluated all radiological images. The frequency of metastasis during the follow-up period in tumors with well- and ill-defined margins was compared using a Fisher’s exact test. The median age at diagnosis was 52.5 years (range, 7–78 years; 20 males). Of the 40 patients, those in their 50 s were the most common (10/40, 25.0%), and the main tumor site was the parotid gland (27/40, 42.5%). Characteristic radiological features included high intensity on T1WI in the cystic components and tumors frequently showed “papillary and cystic,” which showed a projection into the cystic components, or “non-papillary and cystic” morphology, which did not show projection of the solid components. Tumor metastasis was found in 10/35 patients (28.6%) during the follow-up period, with a significant difference in frequency between the tumors with well- and ill-defined margin (well-defined (4/26) vs. ill-defined (6/9); P = 0.0074). MASCs are newly recognized malignant tumors. Characteristic T1WI high intensity on MRI and predominant cystic morphology may reflect its unique histological profile. Ill-defined tumor margin status was related to frequent metastasis. Awareness of these characteristic radiological features can assist radiologists in better detection of this novel entity.
- Published
- 2021
56. Secretory Carcinoma with ETV6-NTRK3 Gene Fusion and Lymph Node Metastasis in Maxillary Gingiva: A Case Report with Pathological and Molecular Correlative Studies.
- Author
-
Fujita J, Krishnan B, Green LK, Sandulache VC, and Lai S
- Subjects
- Humans, In Situ Hybridization, Fluorescence, Gingiva pathology, Lymphatic Metastasis, Oncogene Proteins, Fusion genetics, Biomarkers, Tumor genetics, Translocation, Genetic genetics, Gene Fusion genetics, Carcinoma chemistry, Mammary Analogue Secretory Carcinoma genetics, Salivary Gland Neoplasms genetics, Salivary Gland Neoplasms pathology
- Abstract
Secretory carcinoma (SC), also known as mammary analogue secretory carcinoma (MASC), is a rare salivary gland neoplasm with distinctive morphology that harbors a diagnostic ETV6 gene rearrangement. MASC was first described as a type of salivary gland neoplasm in 2010 and resembles breast secretory carcinoma. It is often mistaken for other neoplasms. It usually acts as an indolent tumor but can occasionally behave in an aggressive manner. We present a rare case of a patient with an aggressive SC/MASC of maxillary gingivobuccal sulcus with microcystic, solid and papillary patterns that showed ETV6 gene rearrangement by fluorescence in situ hybridization. Next-generation sequencing revealed t(12;15)(p13;q25) ETV6-NTRK3 translocation. Because SC/MASCs harbor the ETV6-NTRK3 translocation, molecular studies and immunostains are crucial to confirm the diagnosis and direct therapy., (© 2023 by the Association of Clinical Scientists, Inc.)
- Published
- 2023
57. Mammary Analogue Secretory Carcinoma of the Thyroid Mimicking Locally Advanced Papillary Thyroid Carcinoma: A Rare Case Report.
- Author
-
Haihui Liao, Khan, Ashraf, Miron, Patricia M., and Cornejo, Kristine M.
- Subjects
- *
SALIVARY gland tumors , *DIAGNOSTIC errors , *DIAGNOSTIC immunohistochemistry , *FLUORESCENCE in situ hybridization - Abstract
Mammary analogue secretory carcinoma (MASC) harboring ETV6 gene rearrangements was first described in the salivary gland with a relatively favorable prognosis and a possible molecular therapeutic target with pan-Trk inhibitors. Recently, primary MASC of the thyroid gland has been reported. We report a case of a 4.0 cm MASC arising from the left thyroid of a 58-year-old female with extrathyroidal extension. Initially, it was diagnosed by fine needle aspiration as suspicious for papillary thyroid carcinoma (PTC) and subsequently called a poorly differentiated carcinoma on resection. A final diagnosis of primary MASC of the thyroid was confirmed after an expanded immunohistochemical panel and identification of an ETV6 gene rearrangement by fluorescence in situ hybridization. Morphologically, the tumor was composed of solid, microcystic and focally papillary growth with dense fibrotic stroma and necrosis. Overlapping cytological features with PTC were identified, including foci of enlarged cells with irregular nuclear membranes/grooves. However, most of the cells contained prominent nucleoli with intraluminal and intracytoplasmic eosinophilic secretions. Immunohistochemically, the tumor cells were strongly positive for pancytokeratin, cytokeratin 7, PAX8, mammaglobin, and GCDFP-15, with rare staining for GATA3 and S100 and negative for TTF-1 and thyroglobulin. We report a rare case of a primary thyroid MASC, initially misdiagnosed as PTC. Pathologists should be aware of this entity and, given the similarities to PTC, have a high index of suspicion, prompting the addition of immunohistochemical and molecular studies. Furthermore, an accurate diagnosis is important because of the possible prognostic and treatment implications. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
58. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
- Author
-
Boon, E., Valstar, M.H., van der Graaf, W.T.A., Bloemena, E., Willems, S.M., Meeuwis, C.A., Slootweg, P.J., Smit, L.A., Merkx, M.A.W., Takes, R.P., Kaanders, J.H.A.M., Groenen, P.J.T.A., Flucke, U.E., and van Herpen, C.M.L.
- Subjects
- *
SALIVARY gland cancer , *NECK surgery , *REVERSE transcriptase polymerase chain reaction , *DISSECTION , *CLINICAL trials , *CANCER treatment - Abstract
Objectives: In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma (SC), was defined, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and outcome data of this histological subtype tumor are still sparse, we aimed to describe the clinicopathological course and outcome of a series of translocation positive SC patients.Patient and Methods: We re-evaluated the pathological diagnosis of a subset of SGCs, diagnosed in 4 of 8 Dutch head and neck centers. Subsequently, tumors with a morphological resemblance to SC were tested for the ETV6-NTRK3 fusion gene using RT-PCR. Furthermore, patients prospectively diagnosed with SC were included. The clinical characteristics and outcomes were retrieved from the patient files.Results: Thirty-one patients with ETV6-NTRK3 fusion gene positive SC were included. The median age was 49 years, 17 patients (55%) were male. Eighteen tumors (58%) arose in the parotid gland. One patient presented with lymph node metastasis. All patients underwent tumor resection and 4 patients had a neck dissection. Four patients had re-resection and 15 patients (48%) received postoperative radiotherapy. One patient developed a local recurrence, no regional recurrences or distant metastases were observed. After a median follow-up of 49 months the 5- and 10-year overall survival were 95%, the 5- and 10-year disease free survival were 89%.Conclusion: The clinical course of SC is favorable with a low rate of locoregional recurrence and excellent survival. Given the low incidence of nodal metastases, elective neck treatment, i.e. surgery and/or radiotherapy, does not seem to be indicated. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
59. The screening and electron microscopy observation of mammary analogue secretory carcinoma in Chinese.
- Author
-
Zhong, Yi, Liu, Liu, Qi, Bin, Song, Xiaoling, Shen, Linhan, and Li, Hongwei
- Subjects
SALIVARY gland cancer ,CARCINOMA ,MEDICAL screening ,ELECTRON microscopy ,FLUORESCENCE in situ hybridization - Abstract
Mammary analogue secretory carcinoma of salivary gland (MASC) is a tumor with histopathologic and immunophenotypic features mimicking secretory carcinoma of the breast harboring the ETV6 split. The expression of mammaglobin, S-100, Ki-67, P63 and ETV6 split were detected in twelve cases of acinar cell carcinoma and fourteen cases of mammary analogue secretory carcinoma of salivary gland by immunohistochemistry and fluorescence in situ hybridization respectively. The expression of ETV6 gene split was detected in fourteen mammary analogue secretory carcinomas of salivary gland with positive expression of mammaglobin. Eight of mammary analogue secretory carcinomas of salivary gland also tested positive for the ETV6 gene split via fluorescence in-situ hybridization (FISH). The concordance rate of the immunohistochemistry and FISH was 72.3%. Mammaglobin and ETV6 gene split detection could help to distinguish mammary analogue secretory carcinoma of salivary gland. The mammary analogue secretory carcinoma of salivary gland specimens were also examined under transmission electron microscope. And apical junctional complexes were observed in the loosely connected tumor cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
60. Primary salivary gland malignancies: a review of clinicopathological evolution, molecular mechanisms and management.
- Author
-
Badlani, James, Gupta, Ruta, Balasubramanian, Deepak, Smith, Joel, Luk, Peter, and Clark, Jonathan
- Subjects
- *
SALIVARY gland cancer , *IMMUNOHISTOCHEMISTRY , *FLUORESCENCE in situ hybridization , *CHROMOSOMES , *ADENOID cystic carcinoma - Abstract
Salivary gland cancers are a complex group of tumours with variations in location, type and grade, all of which influence their biological behaviour. The understanding of salivary gland pathology has evolved at the molecular level in the last decade leading to identification of distinct entities, development of improved methods of diagnosis as well as identifying therapeutic targets for selected high‐grade tumours. This article focuses on these advances and their impact on the management of primary salivary gland cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
61. Carcinoma análogo secretor de mama: revisión de diagnóstico y tratamiento a propósito de 2 casos.
- Author
-
Merino Domingo, Francisco, Blanco, María, Zubillaga, Ignacio, Zafra, Víctor, Ballestín, Claudio, and Sánchez Aniceto, Gregorio
- Abstract
Copyright of Revista Española de Cirugía Oral y Maxilofacial is the property of Sociedad Espanola de Cirugia Oral y Maxilofacial (SECOM) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
62. Ultrastructural Characterization of Mammary Analogue Secretory Carcinoma of the Salivary Glands: A Distinct Entity from Acinic Cell Carcinoma?
- Author
-
Guilmette, Julie, Nielsen, Gunnlaugur, Faquin, William, Selig, Martin, Nosé, Vânia, Chi, Anthony, and Sadow, Peter
- Abstract
Mammary analogue secretory carcinoma (MASC) of the salivary glands is a recently described neoplasm of the salivary glands with a characteristic morphology complemented by a specific cytogenetic translocation and gene rearrangements. Although immunophenotypic and cytogenetic differences allow for a more reliable distinction, ultrastructural features can also provide important information about the relationship between MASC, classic acinic cell carcinoma (AciCC), and AciCC intercalated duct cell-predominant variant. Following approval from the hospital's institutional review board, 7 cases of MASC, 8 cases of classic AciCC, and 4 cases of AciCC intercalated duct cell-predominant variant were retrieved from the pathology files of Massachusetts General Hospital from 2012 to 2015. Electron microscopy was performed using formalin-fixed, paraffin-embedded tissue. Ultrastructural features of all 19 neoplasms of the salivary glands were recorded. The predominant cell-types observed in MASC are those with intercalated/striated duct cell differentiation. These features include prominent invaginations of the cell surface studded with microvilli, and some intra- and intercellular lumina also with a microvillous surface. Classic AciCC dominant cell-type recapitulates acinar cell differentiation. These cells contain large intracytoplasmic zymogen-like granules. AciCC intercalated duct cell-predominant variant showed both cell populations in various proportions with the intercalated/striated duct cell type usually being the dominant one. MASC presents with distinctive ultrastructural features that allows its proper differentiation from classic AciCC. However, significant ultrastructural features overlaps between both AciCC intercalated duct cells-predominant and classic AciCC and MASC. These findings indicate a very close proximity between these tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
63. An Underappreciated Cytomorphological Feature of Secretory Carcinoma of Salivary Gland on Fine Needle Aspiration Biopsy: Case Report with Literature Review
- Author
-
Kenneth E Youens, Yinan Hua, Bing Leng, and Lina Liu
- Subjects
Pathology ,medicine.medical_specialty ,Oncogene Proteins, Fusion ,Biopsy, Fine-Needle ,Breast Neoplasms ,Case Reports ,Biology ,Salivary Glands ,Pathology and Forensic Medicine ,Acinic cell carcinoma ,Mucoepidermoid carcinoma ,Biopsy ,Eosinophilic ,Biomarkers, Tumor ,medicine ,Humans ,Histiocyte ,Hyaline ,medicine.diagnostic_test ,Salivary gland ,Carcinoma ,Salivary Gland Neoplasms ,medicine.disease ,Fine-needle aspiration ,medicine.anatomical_structure ,Oncology ,Otorhinolaryngology ,Mammary Analogue Secretory Carcinoma - Abstract
Secretory carcinoma (SC) of salivary gland, previously known as mammary analogue secretory carcinoma, is a rare low-grade malignancy harboring a diagnostic ETV6-NTRK3 gene fusion. SC of salivary gland shares histopathological, immunohistochemical and genetic characteristics with SC of the breast. There are several previous cytomorphological characterizations of SC of salivary gland reported in the literature. The most commonly reported patterns are of epithelial clusters with papillary architectural features, or of single dispersed epithelial cells on a background of abundant histiocytes. Tumor cells exhibit vacuolated eosinophilic cytoplasm and round to oval nuclei with regular nuclear contours and inconspicuous or small nucleoli. The cytomorphology of SC may closely mimic that of acinic cell carcinoma or low-grade mucoepidermoid carcinoma. Moreover, when cohesive epithelial clusters do not appear on the smears, it may be very difficult to distinguish dispersed tumor cells from histiocytes. In this article, we review the literature pertaining to SC cytomorphology and we report a fine needle aspiration biopsy case of SC in salivary gland showing well-defined intracytoplasmic hyaline globules, a feature that has not been previously reported. This novel cytomorphological feature may be helpful in distinguishing the tumor cells of SC from histiocytes and from other low-grade salivary gland tumors.
- Published
- 2021
64. Parotid mammary analogue secretory carcinoma: A case report and review of literature
- Author
-
Yi-Wen Qin, Jia Li, Feng-He Min, Lu Chang, Bo-Qiang Tao, Weiwei Liu, Yuyang Li, Hui-Min Liu, Yingkun Liu, and Zhijing Yang
- Subjects
Pathology ,medicine.medical_specialty ,Mammary analogue secretory carcinoma ,Total lobectomy of right parotid gland ,Lesion ,03 medical and health sciences ,Facial deformity ,0302 clinical medicine ,Case report ,medicine ,Salivary gland ,business.industry ,General Medicine ,Parotidectomy ,medicine.disease ,Facial nerve ,Immunohistochemistry ,Facial paralysis ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,medicine.symptom ,business - Abstract
Background Mammary analogue secretory carcinoma (MASC) is a rare low-grade malignant salivary gland tumor. The morphological and immunohistochemical features of MASC closely resemble those of breast secretory carcinoma. The key characteristics of the lesion are a lack of pain and slow growth. There is no obvious specificity in the clinical manifestations and imaging features. The diagnosis of the disease mainly depends on the detection of the MASC-specific ETV6-NTRK3 fusion gene. Case summary This report describes a rare case of a 32-year-old male patient who presented with a gradually growing lesion that was initially diagnosed as breast-like secretory carcinoma of the right parotid gland. Imaging and histological investigations were used to overcome the diagnostic difficulties. The lesion was managed with right parotidectomy, facial nerve preservation, biological patch implantation to restore the resulting defect, and postoperative radiotherapy. On postoperative follow-up, the patient reported a mild facial deformity with no complications, signs of facial paralysis, or Frey's syndrome. Conclusion The imaging and histological diagnostic challenges for MASC are discussed.
- Published
- 2021
65. Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features
- Author
-
Oliver Bissinger, Carolin Götz, Andreas Kolk, Henning A. Bier, Abbas Agaimy, Henning Frenzel, Sven Perner, Julika Ribbat-Idel, Klaus Dietrich Wolff, Wilko Weichert, and Caroline Mogler
- Subjects
mammary analogue secretory carcinoma ,salivary gland carcinomas ,mammaglobin ,ETV-6 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Mammary analogue secretory carcinoma (MASC) is a newly defined entity among salivary gland malignancies which has just been established in the 4th edition of the WHO classification of head and neck tumors. MASC (synonym: secretory carcinoma) are characterized by a specific rearangement of the ETV6 gene locus. Here, we present a series of 3 MASC cases including clinical data with follow-up for up to 26 months. All tumours immunhistochemically displayed strong positivity for cytokeratin 7, and mammaglobin, focal positivity for S100, cytokeratin 5/6 and muc-4. In contrast, immunhistochemical stainings against cytokeratin 14, hormon receptors, Her2/neu, androgen receptor and prostate-specific antigen were consistently negative. FISH analysis showed translocation of the ETV6 gene locus in the majority of tumour cell nuclei. During clinical follow-up, no local relapse or metastasis was detected. As these carcinomas are clinically and radiologically indistinguishable from other salivary gland tumours and as therapeutic approaches and prognosis might differ, we need to be able to diagnose MASC correctly.
- Published
- 2017
- Full Text
- View/download PDF
66. A Case Report of Mammary Analogue Secretory Carcinoma with Aggressive Clinical and Histological Presentation
- Author
-
Daliah Abdulhafeez and Abdullah Ghafouri
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Mammary analogue secretory carcinoma ,medicine ,Presentation (obstetrics) ,business - Abstract
Mammary analogue secretory carcinoma is a rare salivary gland tumor that has a wide range of clinical presentation ranging from indolent, local and slowly growing tumors to a very aggressive, infiltrative and widely metastasizing forms. We report a case of an unfortunate patient whose tumor had a very quick ominous disease course with aggressive clinical and histological presentation. This case is the first case, to our knowledge, to be reported in the literature from Saudi Arabia of MASC with features of high grade transformation
- Published
- 2021
67. Mammary analogue secretory carcinoma of parotid gland: Literature review and experience of a dedicated cancer institution in Pakistan
- Author
-
null Hamza Shahid, null Rahim Dhanani, null Muhammad Faisal, null Abdul Rehman, null Arif Jamshed, and null Raza Hussain
- Subjects
Adult ,Male ,Young Adult ,Adolescent ,Lymphatic Metastasis ,Humans ,Parotid Gland ,Female ,Pakistan ,General Medicine ,Mammary Analogue Secretory Carcinoma ,Middle Aged ,Salivary Gland Neoplasms - Abstract
Mammary Analogue Secretory Carcinoma (MASC) is a rare pathology of the salivary gland, most commonly involving the parotid gland. The objective of this study was to identify the characteristic features of MASC and its treatment outcomes. A retrospective review of 12 patients with histological diagnosis of MASC, who were managed between 2010 to 2019, was carried out at the Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore. Their mean age was 34 (±16) years. There were 9 (75%) male and 3 (25%) female patients. Painless slow growing swelling was the most common presenting symptom. All the patients had undergone surgical excision with or without neck dissection, followed by adjuvant treatment. Of these, six patients had T2 tumours, while four had cervical lymph node metastasis. The mean follow-up period was 23 (±21) months. Local recurrence was seen in one patient. MASC is considered a low-grade tumour with good prognosis which can be treated with curative intent of surgery followed by radiotherapy effectively. Keywords: Mammary analogue secretory carcinoma, Parotid gland, Salivary tumour.
- Published
- 2022
68. Mammary analogue secretory carcinoma: A diagnostic pitfall on cytopathology
- Author
-
Kadkol Girish A
- Subjects
Pathology ,medicine.medical_specialty ,Cytopathology ,business.industry ,Mammary analogue secretory carcinoma ,medicine ,General Medicine ,business - Published
- 2021
69. A Case of Mammary Analogue Secretory Carcinoma of the Upper Lip
- Author
-
Hideaki Nishi, Tomoyuki Adachi, Masashi Hisanaga, and Yoshihiko Kumai
- Subjects
Pathology ,medicine.medical_specialty ,Otorhinolaryngology ,business.industry ,Mammary analogue secretory carcinoma ,Upper lip ,Medicine ,business - Published
- 2021
70. Large lipid-rich mammary analogue secretory carcinoma of parotid gland: An unusual case
- Author
-
Prashant Joshi, Asit Ranjan Mridha, Shuchita Singh, Prateek Kinra, Ruma Ray, and Alok Thakar
- Subjects
Acinic cell carcinoma ,mammary analogue secretory carcinoma ,parotid gland ,Pathology ,RB1-214 ,Microbiology ,QR1-502 - Abstract
Mammary analogue secretory carcinoma (MASC) of the salivary gland is a malignant tumor which bears morphologic, immunohistochemical and molecular features similar to those of mammary secretory carcinoma. The tumor is considered as a low-grade malignancy perhaps slightly more aggressive than acinic cell carcinoma. High-grade transformation with recurrences, regional nodal involvement, metastases, and cancer-related death has been reported in a few cases. We report an unusual case of large MASC of the parotid gland in a young patient without regional lymph node involvement. To the best of our knowledge till date such a large MASC of the salivary gland has not been reported in the English literature.
- Published
- 2015
- Full Text
- View/download PDF
71. MUC4 is a valuable marker for distinguishing secretory carcinoma of the salivary glands from its mimics
- Author
-
Monica Lorenzon, Alena Skálová, Alessandro Franchi, Cecilia Taverna, Martina Baněčková, Abbas Agaimy, and Annarita Palomba
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Histology ,SOX10 ,Biology ,Salivary Glands ,Pathology and Forensic Medicine ,Acinic cell carcinoma ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Mammaglobin ,Major Salivary Gland ,secretory carcinoma ,acinic cell carcinoma ,Biomarkers, Tumor ,medicine ,Carcinoma ,Humans ,intraductal carcinoma ,Mucin-4 ,Salivary gland ,Carcinoma, Acinar Cell ,Mammaglobin A ,General Medicine ,Salivary Gland Neoplasms ,medicine.disease ,mammaglobin ,030104 developmental biology ,medicine.anatomical_structure ,MUC4 ,030220 oncology & carcinogenesis ,immunohistochemistry ,polymorphous adenocarcinoma ,biology.protein ,Immunohistochemistry ,Adenocarcinoma ,Mammary Analogue Secretory Carcinoma - Abstract
Aims Secretory carcinoma (SC) (synonym: mammary analogue secretory carcinoma) is a low-grade salivary gland tumour that occurs in both major and minor salivary glands. SC is known for its wide morphological, architectural and immunohistochemical spectrum, which overlaps with those of several salivary gland neoplasms, including acinic cell carcinoma (AciCC) and intercalated duct-type intraductal carcinoma (IDC) in major salivary glands, and polymorphous adenocarcinoma (PAC) in minor salivary glands. These tumours share with SC some morphological features and SOX10 immunoreactivity; also, with the exception of AciCC, they all coexpress S100 and mammaglobin. Methods and results We compared MUC4 and mammaglobin expression in 125 salivary gland carcinomas (54 genetically confirmed SCs, 20 AciCCs, 21 PACs, and 30 IDCs) to evaluate the potential of these two markers to differentiate these entities. Moderate to strong diffuse MUC4 positivity was detected in 49 SCs (90.7%), as compared with none of the IDCs and PACs. In contrast, mammaglobin was frequently expressed in SCs (30 of 36 cases; 83.3%), IDCs (24/28; 85.7%), and PACs (7/19; 36.8%). Two of three high-grade SCs lost MUC4 expression in the high-grade tumour component. No significant correlation was found between MUC4 expression and the fusion variant in SC (ETV6-NTRK versus non-ETV6-NTRK). Conclusion The results of our study identify MUC4 as a sensitive (90.7%) and specific (100%) marker for SC, with high positive (100%) and negative (93.4%) predictive values. Thus, MUC4 may be used as a surrogate for SC in limited biopsy material and in cases with equivocal morphology.
- Published
- 2020
72. Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features.
- Author
-
Bissinger, Oliver, Götz, Carolin, Kolk, Andreas, Bier, Henning A., Agaimy, Abbas, Frenzel, Henning, Perner, Sven, Ribbat-Idel, Julika, Wolff, Klaus Dietrich, and Weichert, Wilko
- Subjects
- *
SALIVARY gland tumors , *IMMUNOSTAINING , *ANDROGEN receptors - Abstract
Mammary analogue secretory carcinoma (MASC) is a newly defined entity among salivary gland malignancies which has just been established in the 4th edition of the WHO classification of head and neck tumors. MASC (synonym: secretory carcinoma) are characterized by a specific rearangement of the ETV6 gene locus. Here, we present a series of 3 MASC cases including clinical data with follow-up for up to 26 months. All tumours immunhistochemically displayed strong positivity for cytokeratin 7, and mammaglobin, focal positivity for S100, cytokeratin 5/6 and muc-4. In contrast, immunhistochemical stainings against cytokeratin 14, hormon receptors, Her2/neu, androgen receptor and prostate-specific antigen were consistently negative. FISH analysis showed translocation of the ETV6 gene locus in the majority of tumour cell nuclei. During clinical follow-up, no local relapse or metastasis was detected. As these carcinomas are clinically and radiologically indistinguishable from other salivary gland tumours and as therapeutic approaches and prognosis might differ, we need to be able to diagnose MASC correctly. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
73. Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin.
- Author
-
Baghai, F., Yazdani, F., Etebarian, A., Garajei, A., and Skalova, A.
- Subjects
- *
CARCINOMA , *SALIVARY gland tumors , *ADENOCARCINOMA , *IMMUNOSTAINING , *METASTASIS , *LYMPH nodes , *PROTEIN-tyrosine kinases - Abstract
Background Mammary analogue secretory carcinoma (MASC) is a newly recognized salivary gland tumor that harbors a characteristic balanced chromosomal translocation t (12; 15) (p13; q25) resulting in an ETV6-NTRK3 fusion gene. Methods Retrospective study of 111 salivary gland carcinomas revealed 37 cases with secretory features and growth patterns resembling secretory carcinoma of breast. These 37 cases were originally diagnosed as acinic cell carcinoma, adenocarcinoma not otherwise specified and cystadenocarcinoma. Positive immunostaining for S-100 protein and mammaglobin, followed by detection of ETV6 gene rearrangement by FISH and/or ETV6-NTRK3 fusion transcript by RT-PCR were used to identify MASCs. Results In the cohort of 37 salivary carcinomas with secretory features we have identified 10 cases of MASC. All 10 MASCs were positive for mammaglobin, S-100 protein and SOX10, while staining for DOG1 and p63 protein were mostly absent. In 7/10 cases, both FISH and RT-PCR were positive while three remaining cases showed break of ETV6 gene by FISH analysis and the RT-PCR was negative. Clinical follow-up data were obtained in 6 out of 10 patients with MASC. In 3 patients cervical lymph node metastases developed, one patient with high grade transformed MASC died with multiple distant bone metastases, and local recurrence was observed in three patients. Conclusion Our clinicopathological data are in keeping with previous studies; in most cases, MASC is a low-grade malignancy with overall favorable prognosis. In rare cases, however, MASC with high-grade transformation may behave aggressively, and these patients could benefit from targeted biological treatment using tyrosine kinase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
74. A systematic review including an additional pediatric case report: Pediatric cases of mammary analogue secretory carcinoma.
- Author
-
Ngouajio, Amanda L., Drejet, Sarah M., Phillips, D. Ryan, Summerlin, Don-John, and Dahl, John P.
- Subjects
- *
PAROTID glands , *DUCTAL carcinoma , *CANCER invasiveness , *CHILDHOOD cancer , *MAMMARY gland cancer , *DIAGNOSIS , *CANCER , *CANCER risk factors - Abstract
Importance Mammary Analogue Secretory Carcinoma (MASC) is a newly characterized salivary gland carcinoma resembling secretory carcinoma of the breast. Prior to being described, MASC was most commonly misdiagnosed as Acinic Cell Carcinoma. Though MASC is predominantly an adult neoplasm, cases have been reported in the pediatric population. Reporting and summarizing of known cases is imperative to understand the prognosis and clinical behavior of MASC. Objective (1) Report a rare case of pediatric MASC. (2) Review and consolidate the existing literature on MASC in the pediatric population. Evidence review Web of Science, Medline, EMBASE, and The Cochrane Library were searched for studies that included pediatric cases of MASC. Data on clinical presentation, diagnosis and management, and pathology were collected from all pediatric cases. Findings Case Report 14 year old with left-sided parotid mass diagnosed as MASC based on histology and immunohistochemistry. He was managed surgically with left superficial parotidectomy with selective neck dissection. Literature review The majority of MASC cases have been identified via retrospective reclassification of previously misclassified salivary gland tumors. Of all the pediatric cases (N=11) of MASC, the female-to-male ratio is 1:1.2 with an age range of 10-17 years old. The most common clinical presentation was a slowly growing, fixed, and painless mass of the parotid gland, often detected incidentally on physical examination. Common pathological features include eosinophilic vacuolated cytoplasm within cystic, tubular, and/or papillary architecture. Immunohistochemistry showed positivity for S100, mammaglobin, cytokeratin 19, and vimentin. The diagnosis was confirmed by the detection of the characteristic ETV6-NTRK6 fusion gene via fluorescent in-situ hybridization (FISH). Only 4 cases discussed treatment. Each of these underwent successful surgical resection alone with or without lymph node dissection. Conclusions and relevance Since the first case of MASC in the pediatric population was described in 2011, only 12 cases, including this one, have been described in the literature. With this paucity of information, much remains unknown regarding this new pathologic diagnosis. The collection of clinical outcomes data of children with MASC is needed to better understand the behavior of this malignancy as well as determine optimal treatment regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
75. Combined DOG1 and Mammaglobin Immunohistochemistry Is Comparable to ETV6-breakapart Analysis for Differentiating Between Papillary Cystic Variants of Acinic Cell Carcinoma and Mammary Analogue Secretory Carcinoma.
- Author
-
Said-Al-Naief, Nasser, Carlos, Roman, Vance, Gail H., Miller, Caroline, and Edwards, Paul C.
- Subjects
- *
SALIVARY gland tumors , *IMMUNOHISTOCHEMISTRY , *FLUORESCENCE in situ hybridization , *MAMMARY gland proteins , *GENE rearrangement , *CYSTS (Pathology) , *ENDOPLASMIC reticulum , *DIAGNOSIS - Abstract
Background. We investigated the reliability of combined DOG1 and mammaglobin immunohistochemistry compared with ETV6 fluorescence in situ hybridization (FISH) in the assessment of salivary tumors previously diagnosed as acinic cell carcinoma (ACC). Ultrastructural features of cases reclassified as mammary analogue secretory carcinoma (MASC) were assessed by transmission electron microscopy (TEM). Methods. Immunohistochemical (IHC) reactivity to DOG1 and mammaglobin was validated against FISH targeting the ETV6 gene in all 14 cases. Results. Three cases with papillary cystic histomorphology previously diagnosed as ACC were revised to MASC. TEM features of the ETV6 rearrangement-positive MASC cases showed large numbers of secretory granules with extrusion into the intercellular spaces, well-developed endoplasmic reticulum, lipid-laden vacuoles, well-formed microvilli, and large lining cystic spaces. Conclusions. Combined DOG1 and mammaglobin immunohistochemistry is comparable to ETV6-breakapart analysis for differentiating between papillary cystic variants of ACC and MASC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
76. Mammary Analogue Secretory Carcinoma Presenting as a Cervical Lymph Node Metastasis of Unknown Primary Site: A Case Report.
- Author
-
Suzuki, Kensuke, Yagi, Masao, Kanda, Akira, Kobayashi, Yoshiki, Konishi, Masaya, Miyasaka, Chika, Tashiro, Takashi, and Iwai, Hiroshi
- Subjects
- *
SALIVARY glands , *COMPUTED tomography - Abstract
Background: Mammary analogue secretory carcinoma (MASC) is a pathological entity arising in the salivary glands first described by Skalova et al. [Am J Surg Pathol 2010;34:599-608]. Here, we report the first case of MASC presenting as a cervical lymph node metastasis of unknown primary site together with a brief review of the literature. Case Report: We present a 74-year-old male with a painless lump in his left neck. Based on the fine-needle aspiration cytological findings, a possible malignant tumor was suspected. No evidence of a primary lesion was observed using imaging modalities including positron emission tomography/ computed tomography. The patient underwent an ipsilateral modified radical neck dissection. Immunohistochemical staining showed that the neoplastic cells were positive for S100 protein and GATA3. A rearrangement of the ETV6 gene was noted during fluorescence in situ hybridization, and the final histopathological diagnosis was MASC. Conclusion: We encountered a MASC presenting as a cervical lymph node metastasis of unknown primary site. No adjuvant therapy was administered, and no local recurrence or metastatic diseasehas been detected during a follow-up period of 9 months. This is the first case report of MASC presenting as a cervical lymph node metastasis of unknown primary site and suggests the new properties of MASC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
77. Atypical Presentation of Mammary Analogue Secretory Carcinoma of the Lip
- Author
-
Abdulkader Yassin-Kassab, Ahmed Saeed Sufyan, and Danielle Gainor
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Acinic cell carcinoma ,Pleomorphic adenoma ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Mucoepidermoid carcinoma ,medicine ,Humans ,030304 developmental biology ,0303 health sciences ,Salivary gland ,Carcinoma, Acinar Cell ,business.industry ,Mammary analogue secretory carcinoma ,Not Otherwise Specified ,Salivary Gland Neoplasms ,medicine.disease ,Lip ,medicine.anatomical_structure ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Adenocarcinoma ,Carcinoma, Mucoepidermoid ,Mammary Analogue Secretory Carcinoma ,Presentation (obstetrics) ,business - Abstract
Mammary analogue secretory carcinoma (MASC) of the salivary gland is a rare tumor that was first described by Skalova et al in 2010, and since then, only a few hundred cases have been reported in the literature. Prior to Skalova’s report, MASC was histologically misclassified as acinic cell carcinoma (ACC), pleomorphic adenoma, mucoepidermoid carcinoma, or adenocarcinoma, not otherwise specified. Mammary analogue secretory carcinoma has a low incidence rate overall, accounting for less than 0.3% of all salivary gland tumors. Histopathologic and cytogenic analysis of MASC is identical to secretory carcinoma of the breast, leading to the proposed name by Skalova. The purpose of this case presentation is to describe an atypical presentation of MASC, to compare this case with the classic description of MASC, and to contrast the various features of MASC to ACC in order to improve the accuracy of future diagnoses and help guide treatment.
- Published
- 2020
78. MR imaging findings of a rare pediatric parotid tumor: Mammary analogue secretory carcinoma
- Author
-
Osama Raslan, Angela Vong, Daniel Helmy, John W. Bishop, Arzu Ozturk, and Jennifer Chang
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,Pathology ,medicine.medical_specialty ,Mammary analogue secretory carcinoma ,lcsh:R895-920 ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Magnetic resonance imaging ,stomatognathic system ,Medicine ,Radiology, Nuclear Medicine and imaging ,Salivary gland ,Pediatric ,medicine.diagnostic_test ,business.industry ,Mass ,Mr imaging ,Solid component ,Parotid gland ,medicine.anatomical_structure ,business ,030217 neurology & neurosurgery ,Secretory Breast Carcinoma ,Pediatric population ,Head and Neck - Abstract
We present magnetic resonance imaging findings of an 11-year-old girl with a mammary analogue secretory carcinoma (MASC) of the parotid gland. MASC is a recently described tumor of the salivary glands that is genetically and histologically similar to secretory breast carcinoma. To date, a few cases have been reported in the pediatric population, with limited information of its imaging characteristics. We suggest that decreased T2 signal of the solid component of the MASC representing cellular components with associated complex cystic parts may be a helpful imaging finding and can make a substantial contribution in differentiating this new entity from other rare pediatric parotid masses. Although there are no characteristic imaging findings at this time, MASC should be considered in the differential of salivary gland tumors in the pediatric population as well.
- Published
- 2020
79. Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review)
- Author
-
S. О. Podvyaznikov, A. V. Ignatova, Yu. V. Alymov, and A. M. Mudunov
- Subjects
0301 basic medicine ,Cancer Research ,entrectinib ,medicine.medical_treatment ,polymerase chain reaction ,Entrectinib ,Disease ,law.invention ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,law ,tyrosine kinase inhibitors ,Medicine ,mammary analogue secretory carcinoma ,Pharmacology (medical) ,Radiology, Nuclear Medicine and imaging ,Gene ,larotrectinib ,Polymerase chain reaction ,etv6-ntrk3 ,RC254-282 ,Salivary gland ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,fluorescent in situ hybridization ,immunohistochemistry ,Cancer research ,Immunohistochemistry ,Surgery ,next-generation sequencing ,business ,Tyrosine kinase - Abstract
Mammary analogue secretory carcinoma (MASC) of the salivary gland is a rare salivary cancer, histologically resembling to secretory carcinoma of the breast. In 2017 World Health Organization reported MASC is a new salivary cancer subtype. The aim of this article is to collect and analyze data about MASC, particularly clinical, histological and molecular profile, to evaluate targeted therapy effects. We discuss a case report of dramatic and durable response with entrectinib and the development of acquired resistance in an NTRK3-fusion positive salivary cancer, detected by next-generation sequencing. Next-generation sequencing as a comprehensive molecular profiling, that helps to investigate molecular profile of rare tumors and gives an opportunity to use an effective therapeutic options. Identifying ETV6-NTRK3 positive MASC provides a better prognosis for metastatic disease by using a novel effective targeted therapy with tyrosine kinase inhibitors (entrectinib, larotrectinib). Despite a durable and dramatic response, we showed an interesting case of the development of acquired resistance to tyrosine kinase inhibitors mediated by the appearance of a novel NTRK3 G623R mutation. Finally, we believe in great perspectives of comprehensive molecular profiling and targeted therapy for rare malignancies with NTRK gene fusions, including second-generation tyrosine kinase inhibitors.
- Published
- 2020
80. Primary Mammary-Analogue Secretory Carcinoma of the Lung: A Rare Entity With an Unusual Location
- Author
-
Gillian Alex, Fernando Alekos Ocampo, Josean Ramos, Paolo Gattuso, and Waqas Mahmud
- Subjects
Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Pathology and Forensic Medicine ,Neoplasms, Multiple Primary ,Lesion ,Cytokeratin ,Mammaglobin ,Eosinophilic ,medicine ,Humans ,Lupus Erythematosus, Systemic ,Lymph node ,Lung ,medicine.diagnostic_test ,biology ,business.industry ,Smoking ,Middle Aged ,medicine.anatomical_structure ,Hypertension ,Carcinoma, Squamous Cell ,biology.protein ,Immunohistochemistry ,Female ,Surgery ,Mammary Analogue Secretory Carcinoma ,Anatomy ,medicine.symptom ,business ,Fluorescence in situ hybridization - Abstract
This is a case of a 55-year-old female with past medical history of tobacco smoking, hypertension, and lupus who presented with a left lung nodule, found on computed tomographic scan of the chest during workup for a recently diagnosed squamous cell carcinoma in a cervical lymph node. Resection of the lung nodule showed a 2.3-cm well-defined pale-tan mass, and histologic examination showed a well-circumscribed lesion with papillary, solid, and gland-like architectural patterns, with eosinophilic secretions, areas of comedonecrosis, and increased mitotic activity. Immunohistochemical stains showed the lesion to be positive for cytokeratin 7, S100 protein, and focally positive for mammaglobin. Fluorescence in situ hybridization studies confirmed rearrangement of the ETV6 gene at 12p13.2. To date, our case is the second reported case of a primary mammary-analogue secretory carcinoma arising in the lung, and the first to show evidence of tumor necrosis: an unusual feature in an unusual location.
- Published
- 2020
81. Outcomes of treatment of mammary analogue secretory carcinoma of the parotid gland
- Author
-
J.H. Kim, Dong-Suk Lee, Tae-Mi Yoon, Joon-Kyoo Lee, and S.C. Lim
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Resection ,03 medical and health sciences ,0302 clinical medicine ,Mammaglobin ,stomatognathic system ,Biomarkers, Tumor ,medicine ,Humans ,Parotid Gland ,030223 otorhinolaryngology ,Retrospective Studies ,Salivary gland ,biology ,business.industry ,Mammary analogue secretory carcinoma ,Salivary Gland Neoplasms ,Aspiration cytology ,Parotid gland ,Radiation therapy ,Treatment Outcome ,medicine.anatomical_structure ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,biology.protein ,Immunohistochemistry ,Surgery ,Mammary Analogue Secretory Carcinoma ,Radiology ,Neoplasm Recurrence, Local ,Oral Surgery ,business - Abstract
Mammary analogue secretory carcinoma (MASC) of the salivary gland is a newly-described, rare, malignant tumour. Few patients present with MASC of the parotid gland, so the exact characteristics, outcomes of treatment, and prognosis are unknown. The aim of this study was to analyse the clinical features and outcomes of treatment of MASC of the parotid gland in patients being treated at a single hospital. Five patients with histopathologically-confirmed MASC of the parotid gland between January 2015 and August 2018 were retrospectively enrolled. In all cases preoperative fine-needle aspiration cytology had failed to provide an accurate diagnosis. All patients underwent a macroscopically complete oncological resection. Two patients had postoperative radiotherapy (RT). On immunohistochemical examination all tumours stained for S-100 and mammaglobin but not for DOG1. There were no regional recurrences or distant metastases in any of the patients at their last follow-up. We obtained good results for patients with MASC of the parotid gland with surgical treatment and postoperative RT.
- Published
- 2020
82. Mammary analogue secretory carcinoma in minor salivary gland
- Author
-
Ponso, Lucas Moreno, Zerbinatti, Victor Pereira, Petrarolha, Sílvia Miguéis Picado, Loureiro, Vania, and Dedivitis, Rogério Aparecido
- Subjects
Salivary gland neoplasms ,stomatognathic diseases ,Mammary analogue secretory carcinoma ,stomatognathic system ,Carcinoma ,Salivary glands, minor - Abstract
Mammary analogue secretory carcinoma is a rare neoplasm usually confused with other neoplasms in the salivary glands region. It has great similarity with the breast carcinoma. We report a case of a patient who presented with gingival submucosal bleeding and lesion, with the initial histopathological examination revealing salivary gland neoplasm of low crane. Computed tomography revealed the lesion near the tooth 27, with extension to the floor of the left maxillary sinus and to the palate mucosa. Resection of the infra-structure was performed, with a diagnosis of breast cancer secretory carcinoma in the minor salivary gland.
- Published
- 2022
83. Prognostic factors in mammary analogue secretory carcinomas of the parotid gland: Systematic review and meta-analysis
- Author
-
Stefan Janik, Muhammad Faisal, Blazen Marijić, Stefan Grasl, Matthaeus Ch. Grasl, Gregor Heiduschka, and Boban M. Erovic
- Subjects
Male ,mammary analogue secretory carcinoma ,MASC ,secretory carcinoma ,parotid gland ,prognosis ,outcome ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Otorhinolaryngology ,prognostic factors ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Otorinolaringologija ,Prognosis ,Parotid Neoplasms ,Otorhinolaryngology ,Humans ,Parotid Gland ,Mammary Analogue Secretory Carcinoma ,Neoplasm Staging ,Retrospective Studies - Abstract
Mammary analogue secretory carcinomas (MASCs) of the parotid gland are considered as low-grade malignancies with good clinical outcome but lacking data regarding prognostic factors. We performed meta-analysis assessing prognostic factors for disease-free survival (DFS) and overall survival (OS) in 256 patients with MASCs of the parotid gland. A total of 73 studies have met the inclusion criteria and 76.3% of patients were seen with T1 and T2 tumors and negative neck nodes. Lymph node metastasis (57.4%) and distant recurrences (46.2%) were particularly found in T4 tumors (p < 0.001). DFS at 5 and 10 years was 77.9% and 47.2% compared to 88.1% and 77.2% for OS at the same time points. Male sex, T3-T4 tumors, and recurrent disease represented independent worse prognosticators for survival outcome. Altogether, parotid gland MASCs show the good long-term outcomes, but T4 tumors behave significantly more aggressive and require extended treatment strategies along with close follow-ups.
- Published
- 2021
84. Secretory carcinoma of the sinonasal cavity and pharynx: A retrospective analysis of four cases and literature review
- Author
-
Changli, Yue, Xiaoli, Zhao, Donglin, Ma, and Yingshi, Piao
- Subjects
Oncogene Proteins, Fusion ,Carcinoma ,Biomarkers, Tumor ,Humans ,Pharynx ,Mammary Analogue Secretory Carcinoma ,General Medicine ,Salivary Gland Neoplasms ,Immunohistochemistry ,In Situ Hybridization, Fluorescence ,Retrospective Studies ,Pathology and Forensic Medicine - Abstract
Secretory carcinoma (SC) is a recently recognized type of salivary gland tumor characterized by t(12;15) (p13;q25) translocation resulting in an ETV6-NTRK3 gene fusion. Most SCs are located in a main salivary gland, and primary sinonasal secretary carcinoma is rare. We describe three cases of primary SC in the sinonasal cavity with high-grade transformation (HGT) in one case, and the first case in the pharynx. All tumors comprised slightly atypical cells with solid, tubular, microcystic growth patterns. The case with HGT included two components with distinct sharp boundaries and comedo necrosis, high mitotic figures and obvious cellular atypia. Tumor cells were positive for vimentin, S100, and Gata-3 and negative for p63 and DOG-1. Three cases showed nuclear staining of pan-TRK and one showed cytoplasmic staining. All cases harbored ETV6 gene rearrangement, and ETV6-NTRK3 gene fusion was detected in three cases. Most patients were treated with radical resection and adjuvant therapy. After excision, all remained tumor-free for 65-164 months (medium 98.5 months). SC in the sinonasal cavity and pharynx is a low-grade malignant tumor with histologic features overlapping those of other salivary gland tumors. Immunohistochemical analysis and fluorescence in situ hybridization are useful techniques for its differential diagnosis.
- Published
- 2022
85. Cytomorphological features of Mammary Analog secretory carcinoma of parotid gland: Report of 3 cases and review of literature
- Author
-
Shilpy, Jha, Swagatika, Samal, Pavithra, Ayyanar, Pritinanda, Mishra, Suvendu, Purkait, Mukund N, Sable, Pradeep, Pradhan, and Amit Kumar, Adhya
- Subjects
Adult ,Diagnosis, Differential ,Male ,Adolescent ,Humans ,Parotid Gland ,Female ,Mammary Analogue Secretory Carcinoma ,Parotid Neoplasms - Abstract
Mammary analog secretory carcinoma (MASC) of salivary gland is a recently described entity. Due to its rarity and cytomorphological overlap with other salivary gland tumors, it is often difficult to recognize on cytology. Here we describe three such cases with their histopathological correlation. All the three tumors arose in the parotid gland. They were misdiagnosed as mucoepidermoid carcinoma, acinic cell carcinoma and salivary duct adenocarcinoma, respectively. Final diagnosis of MASC was established on their follow-up histopathology and immunochemistry evaluation. Cytosmears of these tumors showed high cellularity with papillary architecture lying within fluid background rich in foamy macrophages. Nuclear atypia varied from minimal to marked with frequent mitosis and presence of necrosis. Cytoplasmic vacuolation was a consistent finding. Although the cytomorphological features of MASC are not specific, a diagnosis of MASC should be strongly considered in the presence of papillary architecture, prominent cytoplasmic vacuolations of the tumor cells and a background of cyst fluid. Immunohistochemistry on cell block may be done to confirm the diagnosis.
- Published
- 2021
86. Imaging identification of primary mammary analogue secretory carcinoma and acinic cell carcinoma in major salivary glands
- Author
-
Qian Yu, Angang Ding, Huan Lv, Shiwen Ding, Lu Zhou, Ping Xiong, and Jiaxin Zuo
- Subjects
Pathology ,medicine.medical_specialty ,Salivary Glands ,Acinic cell carcinoma ,Diagnosis, Differential ,Vascularity ,Major Salivary Gland ,Biomarkers, Tumor ,Medicine ,Humans ,General Dentistry ,Lymph node ,medicine.diagnostic_test ,business.industry ,Carcinoma, Acinar Cell ,Mammary analogue secretory carcinoma ,Echogenicity ,Magnetic resonance imaging ,medicine.disease ,Salivary Gland Neoplasms ,medicine.anatomical_structure ,Otorhinolaryngology ,Mammary Analogue Secretory Carcinoma ,Ultrasonography ,medicine.symptom ,business ,Tomography, X-Ray Computed - Abstract
Objective The present study aimed to characterize and differentiate the ultrasonography (US) and computed tomography (CT) features of mammary analogue secretory carcinoma (MASC) and acinic cell carcinoma (AciCC). Methods and patients A total of 83 patients with clinically proven MASC and AciCC were analyzed. The following characteristics were assessed on US, CT, and magnetic resonance imaging: lesion size, shape, margin, echogenicity, echotexture, cystic components, posterior echo, vascularity, density, degree of enhancement, enhancement pattern, signal intensity (SI) on T1 and T2 weighted images (WI), hemorrhages, and lymph node enlargement. Results Similarities were observed between the imaging performance of MASC and AciCC. Differences between the two characteristics of shape on US and cystic components on CT were statistically significant. The proportion of MASC to regular shape on US (P = 0.006) and cystic components on CT (P = 0.027) was significantly higher than that of AciCC. Regular shape on US had the highest sensitivity in the identification of MASC and AciCC, while regular shape on US + cystic component on CT had the highest specificity. Conclusions The shape on US and cystic components on CT are key characteristics for distinguishing MASC and AciCC.
- Published
- 2021
87. Secretory Carcinoma in Children and Young Adults: A Case Series
- Author
-
Caroline T. Simon, Jonathan B. McHugh, Raja Rabah, and Amer Heider
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Breast Neoplasms ,Malignancy ,Pathology and Forensic Medicine ,Lesion ,Young Adult ,medicine ,Biomarkers, Tumor ,Humans ,Young adult ,Stage (cooking) ,Child ,Lymph node ,business.industry ,Standard treatment ,Carcinoma ,General Medicine ,medicine.disease ,Salivary Gland Neoplasms ,Surgery ,Dissection ,medicine.anatomical_structure ,Pediatrics, Perinatology and Child Health ,Female ,Salivary gland neoplasm ,Mammary Analogue Secretory Carcinoma ,medicine.symptom ,business - Abstract
Secretory carcinoma (SC), previously known as mammary analogue secretory carcinoma, is a rare salivary gland neoplasm that typically presents as a slow-growing painless lesion in the head and neck. SC occurs mainly in adults but has been described in children with the youngest reported patient diagnosed at five years of age. In children the gender distribution has been reported as female to male ratio of 1:1.2. SC is generally considered a low-grade malignancy with characteristic morphological features and immunological profile. SC also harbors ETV6-NTRK3 fusion (t(12;15)(p13:q25)). Surgical resection with or without lymph node dissection is the standard treatment, with generally favorable clinical outcomes. Here we present a single institution case series of six patients (ages 9-21) with SC and a review of the previously described pediatric cases. Our small series showed male predominance in pediatric patients with predominantly low-grade and stage tumors. All cases underwent complete surgical resections and when follow up is available there was no evidence of recurrences or metastases. To the best of our knowledge, this is the only SC case series comprised exclusively of pediatric and youth patients.
- Published
- 2021
88. Mammary analogue secretory carcinoma of a salivary gland of the hard palate with contralateral cervical lymph node metastases: A case report
- Author
-
Julian Hohm, Urs D.A. Müller-Richter, Andreas Fuchs, Roman C. Brands, Stefan Hartmann, Sabrina Strobel, Anton Straub, Alexander C. Kübler, and Christian Linz
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,Malignancy ,Acinic cell carcinoma ,head and neck ,Mammaglobin ,medicine ,mammary analogue secretory carcinoma ,cancer ,Lymph node ,neck dissection ,salivary gland cancer ,biology ,Salivary gland ,business.industry ,Neck dissection ,Articles ,oral cancer ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Salivary gland cancer ,biology.protein ,oral cavity ,Hard palate ,business ,lymph node metastases - Abstract
Mammary analogue secretory carcinoma (MASC) is a rare malignant tumour of the salivary glands, with only few cases reported in the literature to date. Initial preoperative staging is crucial for all patients with an oral malignancy to visualize the tumour, detect lymph node or distant metastases and plan therapeutic interventions. In the case presented herein, radiological imaging revealed a tumour of the right hard palate with suspected positive contralateral lymph nodes. Therefore, local tumour resection comprising hemimaxillectomy and bilateral neck dissection was performed. The diagnosis of MASC was finally based on characteristic histopathological and immunohistochemical findings, such as S100 protein and mammaglobin positivity. The diagnosis of MASC may be challenging, as such findings lack specificity. To confirm the diagnosis, molecular genetic examinations may be performed to detect a highly specific ETV6-NTRK3 fusion gene. Depending on the results of these examinations, surgery, alone or combined with adjuvant radiation or chemoradiation, is the recommended approach. In summary, MASC should be treated similarly to other low-grade salivary gland tumours, such as acinic cell carcinoma, as they exhibit biological and histopathological similarities.
- Published
- 2021
89. Secretory carcinoma of the sinonasal cavity and pharynx: A retrospective analysis of four cases and literature review.
- Author
-
Yue, Changli, Zhao, Xiaoli, Ma, Donglin, and Piao, Yingshi
- Abstract
Secretory carcinoma (SC) is a recently recognized type of salivary gland tumor characterized by t(12;15) (p13;q25) translocation resulting in an ETV6-NTRK3 gene fusion. Most SCs are located in a main salivary gland, and primary sinonasal secretary carcinoma is rare. We describe three cases of primary SC in the sinonasal cavity with high-grade transformation (HGT) in one case, and the first case in the pharynx. All tumors comprised slightly atypical cells with solid, tubular, microcystic growth patterns. The case with HGT included two components with distinct sharp boundaries and comedo necrosis, high mitotic figures and obvious cellular atypia. Tumor cells were positive for vimentin, S100, and Gata-3 and negative for p63 and DOG-1. Three cases showed nuclear staining of pan-TRK and one showed cytoplasmic staining. All cases harbored ETV6 gene rearrangement, and ETV6-NTRK3 gene fusion was detected in three cases. Most patients were treated with radical resection and adjuvant therapy. After excision, all remained tumor-free for 65–164 months (medium 98.5 months). SC in the sinonasal cavity and pharynx is a low-grade malignant tumor with histologic features overlapping those of other salivary gland tumors. Immunohistochemical analysis and fluorescence in situ hybridization are useful techniques for its differential diagnosis. • Primary secretory carcinoma of the sinonasal cavity, and pharynx is rare, • wesought to characterize its clinicapathologic, and molecular features further, with a focus on high-grade transformation and literature review. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
90. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic study of 11 cases.
- Author
-
Din, Nasir Ud, Fatima, Saira, and Kayani, Naila
- Abstract
Mammary analogue secretory carcinoma (MASC) is a recently described tumor sharing the histologic, immunohistochemical, and molecular profile of secretory carcinoma of breast. We aimed to evaluate the morphologic and histochemical features needed/required for the diagnosis of MASC without adjunct of molecular analysis. Six retrospective cases suspicious for MASC and 5 prospective cases reported as MASC were included in the study. Molecular analysis of ETV6 by fluorescence in situ hybridization was performed at the University of Pittsburg, USA. The ages of the patients ranged from 9 to 60 years (mean, 27.5 years). Histologically, all tumors showed mixed growth patterns including microcystic, macrocystic, papillary, tubular, and solid, papillary the being most common pattern. The tumor cells showed round to oval vesicular nuclei with small nucleoli, and eosinophilic to vacuolated cytoplasm. All cases demonstrated luminal and cytoplasmic mucin on periodic acid–Schiff with and without diastase digestion and alcian blue stain. ETV6 fusion gene rearrangement by fluorescence in situ hybridization was detected in 10 of 11 tumors. Recurrences occurred in 3 patients, and 1 patient died of disease 5 years after surgery. In conclusion, MASC is a relatively rare salivary gland malignancy exhibiting distinct histologic and histochemical features which can help to differentiate it from other mimics. Histologically, papillary-cystic and microcystic patterns are the main clues to diagnosis. The follicular pattern of acinic cell carcinoma might represent MASC, as 4 cases in our series had this pattern. Two patients in our series were 9 and 9½ years old respectively, which are the youngest ages ever recorded for MASC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
91. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
- Author
-
Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D. M., Hechtman, J., Wei, G., Cam, N. R., Christiansen, J., Luo, D., Maneval, E. C., Bauer, T., Patel, M., Liu, S. V., Ou, S. H. I., Farago, A., and Shaw, A.
- Subjects
- *
SALIVARY gland tumors , *PROTEIN-tyrosine kinase inhibitors , *TRANSCRIPTION factors , *NEUROTROPHINS , *DRUG resistance in cancer cells , *RARE diseases , *TUMOR treatment - Abstract
Background: Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity. We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as MASC after next-generation sequencing revealed an ETV6-NTRK3 fusion. Patients and methods: This alteration was targeted with the pan-Trk inhibitor entrectinib (Ignyta), which possesses potent in vitro activity against cell lines containing various NTRK1/2/3 fusions. Results: A dramatic and durable response was achieved with entrectinib in this patient, followed by acquired resistance that correlated with the appearance of a novel NTRK3 G623R mutation. Structural modeling predicts that this alteration sterically interferes with drug binding, correlating to decreased sensitivity to drug inhibition observed in cell-based assays. Conclusions: This first report of clinical activity with TrkC inhibition and the development of acquired resistance in an NTRK3-rearranged cancer emphasize the utility of comprehensive molecular profiling and targeted therapy for rare malignancies (NCT02097810). [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
92. 唾液腺非乳腺样分泌癌中乳腺球蛋白的表达及 ETV6 基因重排.
- Author
-
孙晶晶, 田臻, 王丽珍, 张春叶, 张莺, and 李江
- Abstract
Copyright of China Journal of Oral & Maxillofacial Surgery is the property of Shanghai Jiao Tong University, College of Stomatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
93. Carbonic anhydrase VI: a novel marker for salivary serous acinar differentiation and its application to discriminate acinic cell carcinoma from mammary analogue secretory carcinoma of the salivary gland.
- Author
-
Hsieh, Min‐Shu, Jeng, Yung‐Ming, Jhuang, Yu‐Lin, Chou, Yueh‐Hung, and Lin, Chiao‐Ying
- Subjects
- *
SALIVARY gland cancer , *CARBONIC anhydrase , *SEROUS fluids , *PANCREATIC acinar cells , *CANCER cell differentiation , *METASTASIS - Abstract
Aims Carbonic anhydrase VI (CA6) is present in serous acinar cells of human salivary glands. The aim of this study was to investigate the diagnostic utility of CA6 in differentiating acinic cell carcinoma (AciCC) from its morphological mimic mammary analogue secretory carcinoma (MASC) of the salivary gland. Methods and results CA6 immunostaining was performed in 28 cases of AciCC and 14 cases of MASC. All cases of AciCC showed positive CA6 staining. The staining pattern correlated with the number of serous acinar cells in tumours. All MASCs stained negatively for CA6. The results were compared with those obtained with currently used markers, including DOG1, mammaglobin, S100, and vimentin. CA6 showed sensitivity and specificity as high as those of DOG1 in diagnosing AciCC. CA6 expression was focally observed in basal cell adenoma and in one case of cystadenocarcinoma (1/3), but not in other salivary gland tumours, including mucoepidermoid carcinoma, adenoid cystic carcinoma, salivary duct carcinoma, lymphoepithelial carcinoma, epithelial-myoepithelial carcinoma, and pleomorphic adenoma. Conclusions CA6 is a specific marker for serous acinar cells of salivary glands and AciCC. CA6 has sensitivity and specificity equal to those of DOG1 in the differential diagnosis between AciCC and MASC. A combination of CA6 and DOG1 could be an ideal immunohistochemical panel for AciCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
94. Cytopathological Findings of Secretory Carcinoma of the Salivary Gland and the Diagnostic Utility of Giemsa Staining
- Author
-
Egusa, Yuria, Nishimura, Midori Filiz, Baba, Satoko, Takeuchi, Kengo, Makino, Takuma, Tachibana, Tomoyasu, Nishikori, Asami, Fujita, Azusa, Yanai, Hiroyuki, Sato, Yasuharu, Egusa, Yuria, Nishimura, Midori Filiz, Baba, Satoko, Takeuchi, Kengo, Makino, Takuma, Tachibana, Tomoyasu, Nishikori, Asami, Fujita, Azusa, Yanai, Hiroyuki, and Sato, Yasuharu
- Abstract
Secretory carcinoma is a salivary gland neoplasm first described as a mammary analogue secretory carcinoma by Skalova and redesignated as a secretory carcinoma in the 2017 World Health Organization Classification of Head and Neck Tumors. Secretory carcinoma diagnosis is reliant on specific cytological and histological findings and the detection of an ETV6-NTRK3 fusion gene. Here, we examined the clinical and cytopathological features of four cases of secretory carcinoma occurring in three males and a female, aged between 39 and 74 years. All four tumors involved the parotid gland, and were found to have the ETV6-NTRK3 fusion gene. Fine-needle aspiration-based cytology smears of all tumors displayed papillary and/or dendritic pattern clusters, some of which were associated with blood vessels. The neoplastic cells displayed enlarged nuclei with fine chromatin and small, distinct, single nucleoli. Furthermore, several neoplastic cells with a characteristic vacuolated cytoplasm were identified in each specimen. Giemsa staining revealed cytoplasmic vacuolation, intracytoplasmic metachromatic secretions and/or various sized metachromatic granules, and a background of metachromatic mucin in all four specimens. Given this, we conclude that these cytological findings, especially those of the Giemsa staining, might be helpful in the diagnosis of secretory carcinoma.
- Published
- 2021
95. Mammary Analogue Secretory Carcinoma (MASC) of the submandibular gland - a case report
- Author
-
C Mousa, R Magritz, and J Inhestern
- Subjects
Pathology ,medicine.medical_specialty ,medicine.anatomical_structure ,business.industry ,Mammary analogue secretory carcinoma ,medicine ,business ,Submandibular gland - Published
- 2021
96. Concurrent Identification of Novel EGFR–SEPT14 Fusion and ETV6–RET Fusion in Secretory Carcinoma of the Salivary Gland
- Author
-
George Jour, Paolo Cotzia, Maristela L. Onozato, Farbod Darvishian, Margaret Black, Anthony J. Iafrate, and Cheng Z Liu
- Subjects
Male ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,Adolescent ,Case Report ,Biology ,Pathology and Forensic Medicine ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,medicine ,Humans ,Oncogene Fusion ,Gene ,Sanger sequencing ,Proto-Oncogene Proteins c-ets ,Salivary gland ,Proto-Oncogene Proteins c-ret ,RNA ,Histology ,Parotid Neoplasms ,ErbB Receptors ,Repressor Proteins ,Secretory Carcinoma ,ETV6 ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,symbols ,Mammary Analogue Secretory Carcinoma ,Salivary gland neoplasm ,Septins - Abstract
Salivary gland secretory carcinoma, also termed mammary analogue secretory carcinoma (MASC), is a recently described salivary gland neoplasm with characteristic histomorphologic findings similar to those of secretory carcinoma of the breast and harboring recurrent ETV6–NTRK3 fusions. Recent findings have expanded the molecular profile of salivary gland secretory carcinoma to include multiple novel ETV6 fusion partners, including RET, MET, and MAML3. Here, we report a case of cystic MASC with cribriform and papillary histology harboring two gene fusions, ETV6–RET and EGFR–SEPT14, identified by targeted RNA sequencing. The presence of the rearrangements was confirmed by FISH, RT-PCR, and Sanger sequencing. This is the first EGFR–SEPT14 fusion reported in secretory carcinoma as a single event or in association with an ETV6 rearrangement. This finding adds to the expanding molecular profile of this tumor entity, and may translate into novel treatment strategies.
- Published
- 2019
97. (Mammary Analogue) Secretory Carcinoma of the Nasal Cavity: Report of a Rare Case with p63 and DOG1 Expression and Uncommon Exon 4–Exon 14 ETV6-NTRK3 Fusion Diagnosed with Next Generation Sequencing
- Author
-
Michal Michal, Tomas Vanecek, Fredrik Petersson, Bingcheng Wu, and Thomas Kwok Seng Loh
- Subjects
Male ,0301 basic medicine ,Nasal cavity ,Pathology ,medicine.medical_specialty ,Oncogene Proteins, Fusion ,Nose Neoplasms ,Case Report ,Biology ,DNA sequencing ,Pathology and Forensic Medicine ,Fusion gene ,03 medical and health sciences ,Exon ,0302 clinical medicine ,Biomarkers, Tumor ,medicine ,Humans ,Gene ,Anoctamin-1 ,Aged ,Mammary analogue secretory carcinoma ,High-Throughput Nucleotide Sequencing ,Membrane Proteins ,Exons ,Sequence Analysis, DNA ,Neoplasm Proteins ,ETV6 ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Immunohistochemistry ,Mammary Analogue Secretory Carcinoma ,Nasal Cavity - Abstract
We present a 72 years old male with a left nasal cavity (mammary analogue) secretory carcinoma (SC) which exhibited classical morphological features on light microscopical examination, diffuse strong S100 and mammoglobin positivity on immunohistochemistry, and ETV6-NTRK3 gene fusion on next generation sequencing (NGS) analysis. Unusual features of this tumor are expression of p63 and DOG1 on immunohistochemistry and the atypical junction between Exon 4 of the ETV6 gene and Exon 14 of the NTRK3 gene.
- Published
- 2019
98. Mammary analogue secretory carcinoma presenting as a cystic parotid mass
- Author
-
Angela G. Niehaus, Hafiz S. Patwa, Karisma Gupta, Christopher M. Lack, and Gileno O.F. Filho
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,Pathology ,medicine.medical_specialty ,Mammary analogue secretory carcinoma ,lcsh:R895-920 ,030218 nuclear medicine & medical imaging ,Acinic cell carcinoma ,03 medical and health sciences ,0302 clinical medicine ,Magnetic resonance imaging ,stomatognathic system ,medicine ,Radiology, Nuclear Medicine and imaging ,Cyst ,Cystic mass ,medicine.diagnostic_test ,business.industry ,Parotid mass ,ETV6-NTRK3 translocation ,medicine.disease ,FACIAL MASS ,Parotid gland ,medicine.anatomical_structure ,business ,030217 neurology & neurosurgery ,Head and Neck - Abstract
We present a case of a 63-year-old male with an 8-year history of a left-sided cystic facial mass which recurred despite multiple drainage procedures. Imaging findings showed a cystic mass in the left parotid gland and it was surgically resected. Pathology confirmed it to represent a mammary analogue secretory carcinoma, a relatively newly described entity. This case illustrates that mammary analogue secretory carcinoma can masquerade as a cyst within the parotid gland. Keywords: Parotid gland, Mammary analogue secretory carcinoma, Acinic cell carcinoma, ETV6-NTRK3 translocation, Magnetic resonance imaging, Cystic mass
- Published
- 2019
99. Locally advanced mammary analogue secretory carcinoma of the parotid gland
- Author
-
Koh-ichi Nakashiro, Hiroyuki Goda, and Norihiko Tokuzen
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Oncogene Proteins, Fusion ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,Biomarkers, Tumor ,Parapharyngeal space ,Humans ,Parotid Gland ,Medicine ,Stage (cooking) ,Lymph node ,Aged ,Cuboidal Cell ,business.industry ,030206 dentistry ,Salivary Gland Neoplasms ,Parotid gland ,Radiation therapy ,medicine.anatomical_structure ,Otorhinolaryngology ,Fusion transcript ,030220 oncology & carcinogenesis ,Surgery ,Mammary Analogue Secretory Carcinoma ,Oral Surgery ,business ,Orbit (anatomy) - Abstract
Mammary analogue secretory carcinoma (MASC) has recently been recognized as a salivary gland tumour that is characterized by the ETV6–NTRK3 fusion gene. A case of locally advanced MASC of the parotid gland in a 67-year-old man is presented here. The patient visited the hospital due to a large right infra-auricular mass, which had been enlarging gradually over a period of 2 years. Contrast-enhanced computed tomography (CT) demonstrated a multilocular mass, 75 × 63 mm in size, containing a fluid component with non-uniform contrast effects in the interior portion. The mass had invaded the orbit, skull base, and parapharyngeal space. The patient had neither lymph node nor distant metastasis. The tumour showed tubular and ductal proliferation lined by a single layer of neoplastic cuboidal cells with clear foamy cytoplasm. Characteristic hobnail cells were observed. Expression of ETV6–NTRK3 fusion transcript in the tumour tissues was confirmed by RT-PCR. The final diagnosis was MASC (T4bN0M0, stage IVB). The patient received cetuximab together with radiotherapy at a total dose of 66 Gy. After treatment, CT showed a slightly reduced tumour volume, indicating stable disease. More than 56 months after treatment, the patient remains alive with no remarkable change in the tumour.
- Published
- 2019
100. Primary Mammary Analog Secretory Carcinoma (MASC) of the Vulva With ETV6-NTRK3 Fusion
- Author
-
Jesse K. McKenney, Chandrika Joshi, Julia A. Bridge, and Jane K. Nguyen
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Oncogene Proteins, Fusion ,Breast Neoplasms ,Vulva ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,stomatognathic system ,medicine ,Humans ,Vulvar neoplasm ,Vulvar Neoplasms ,business.industry ,Carcinoma ,Thyroid ,Obstetrics and Gynecology ,Middle Aged ,Salivary Gland Neoplasms ,Immunohistochemistry ,Submandibular gland ,Parotid gland ,stomatognathic diseases ,ETV6 ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Mammary Analogue Secretory Carcinoma ,Salivary gland neoplasm ,business - Abstract
Mammary analog secretory carcinoma is a primary salivary gland neoplasm with histologic, immunophenotypic, and molecular features identical to those of secretory carcinoma of the breast. Similar neoplasms have now been reported to occur in various nonmammary sites including the parotid gland, submandibular gland, sinuses, lip, skin, thyroid gland, and lung. We report, to our knowledge, the first example of a primary vulvar neoplasm with pathologic features identical to secretory carcinoma of the breast and an ETV6-NTRK3 fusion.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.